Learning Marketplace

New version of MEDDEV 2.7.1 Revision 4: Key changes and clarification

Revision 4 of the MEDDEV guidance document 2.7.1 was released by the European Commission on 1st July 2016. This document provides information to manufacturers on conducting a clinical evaluation, including demonstration of scientific validity of your data and conclusions. The document also covers requirements specifically for Post-Market Surveillance (PMS), and Post-Market Clinical Follow-Up (PMCF).

While the new version does include some new requirements, the document principally clarifies a number of the existing requirements, providing more detail on what is expected of manufacturers conducting a clinical evaluation. For example, there is more information on state of the art, equivalence and risk-benefit profiles. The new version also includes examples, helping manufacturers to understand what is required.

The new Revision is beginning to align with the European Medical Device Regulation, transition to which will require conformity to the requirements of the new Revision of this guidance.

This webinar will explore the key changes, discussing the new requirements and noting the main clarifications within the guidance document. It will highlight the areas for you to be aware of and consider when conducting clinical evaluations.


Amie Smirthwaite is a Product Technical Specialist and Scheme Manager for the Orthopaedic and Dental team at BSI. She has nearly 20 years' postdoctoral experience, covering new product development, production, quality system management and regulatory affairs within the medical devices industry.

Monisha Phillips is the Global Head of the Orthopaedic & Dental Devices team at BSI. Since joining BSI in 2008, Monisha has experience as a technical specialist in the Orthopaedic & Dental Devices team, and has also spent time as a technical specialist in the General Devices team prior to becoming Global Head.